BioNTech vs Qiagen
BNTX and QGEN side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How BNTX and QGEN compare
Qiagen grew revenue faster over the last twelve months (5.7% versus 4.3% for BioNTech).
Qiagen keeps more of each dollar of sales as profit, with a net margin of 20.3% compared with −39.6% at BioNTech.
Qiagen scores higher on the StockData Score (10 against 3 for BioNTech), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | BNTX | QGEN |
|---|---|---|
| Size and price | ||
| Share price | $88.17 | $50.22 |
| Change, 1 year | −14.7% | 1.1% |
| Change, 5 years | −59.3% | −12.0% |
| Beta (5Y) | 0.82 | 0.69 |
| Employees | 500 | 5,700 |
| StockData Score | ||
| Total score | 3 | 10 (better) |
| Valuation score | 0 | 0 |
| Growth score | 1 | 2 (better) |
| Performance score | 1 | 4 (better) |
| Health score | 1 | 4 (better) |
| Dividend score | 0 | 0 |
| Growth | ||
| Revenue growth (TTM) | 4.3% | 5.7% (better) |
| Revenue growth, 5Y average | 42.9% (better) | 2.2% |
| Net income growth (TTM) | – | 408% |
| EPS growth (TTM) | – | 424% |
| EPS growth, 5Y average | – | 4.9% |
| Profitability | ||
| Gross margin | 77.6% (better) | 62.2% |
| Operating margin | −49.0% | 22.3% (better) |
| Net margin | −39.6% | 20.3% (better) |
| FCF margin | 9.8% | 21.7% (better) |
| Return on equity | – | 11.6% |
| Return on invested capital | – | 9.9% |
| Financial health | ||
| Debt / equity | – | 0.44 |
| Net debt / EBITDA | – | 0.84 |
| Interest coverage | −20.1× | 14.0× (better) |
| Current ratio | 7.54 (better) | 3.90 |
| Piotroski F-score | 5 | 8 (better) |
| Dividends and buybacks | ||
| Payout ratio | – | 12.8% |
| Years of dividend growth | – | 0 |
| Ownership | ||
| Held by institutions | 18.9% | 67.4% |
| Held by insiders | 58.1% | 0.00% |
| Insider net buying, 12 months | −$69.2M | – |
| Short interest, % of float | – | 3.5% |
Go deeper
- BNTX stock overview
- BNTX income statement
- BNTX valuation and score
- QGEN stock overview
- QGEN income statement
- QGEN valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.